PGEN - Precigen Phase 1/2 trial selected as a pivotal study for rare disease therapy
2023-08-09 15:01:02 ET
More on Precigen
- Unraveling The Promise Of Precigen: Biotech Innovations Amid Financial Challenges
- Precigen gains on FDA Breakthrough Therapy Designation
- Precigen gets IND clearance for phase 2 trial of cervical cancer immunotherapy
- Precigen stock jumps ~10% as CAR-T cell therapy's dosing starts in cancer trial
- Precigen posts Phase 1 data for CAR-T therapy in blood cancer
For further details see:
Precigen Phase 1/2 trial selected as a pivotal study for rare disease therapy